Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Non-Current Deferred Tax Liability (2024 - 2025)

Oric Pharmaceuticals filings provide 2 years of Non-Current Deferred Tax Liability readings, the most recent being $220000.0 for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability rose 107.55% to $220000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $220000.0 through Dec 2025, up 107.55% year-over-year, with the annual reading at $220000.0 for FY2025, 107.55% up from the prior year.
  • Non-Current Deferred Tax Liability hit $220000.0 in Q4 2025 for Oric Pharmaceuticals, up from $106000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $220000.0 in Q4 2025 and bottomed at $106000.0 in Q4 2024.